Abstract
BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.
| Original language | English |
|---|---|
| Pages (from-to) | 169-174 |
| Number of pages | 6 |
| Journal | Cancer |
| Volume | 88 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2000 |
Fingerprint
Keywords
- Central neurocytoma
- Chemotherapy
- Recurrent
- Review
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Chemotherapy in patients with recurrent and progressive central neurocytoma. / Brandes, Alba A.; Amistà, Pietro; Gardiman, Marina; Volpin, Lorenzo; Danieli, Daniela; Guglielmi, Bianca; Carollo, Carla; Pinna, Gianpietro; Turazzi, Sergio; Monfardini, Silvio.
In: Cancer, Vol. 88, No. 1, 01.01.2000, p. 169-174.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chemotherapy in patients with recurrent and progressive central neurocytoma
AU - Brandes, Alba A.
AU - Amistà, Pietro
AU - Gardiman, Marina
AU - Volpin, Lorenzo
AU - Danieli, Daniela
AU - Guglielmi, Bianca
AU - Carollo, Carla
AU - Pinna, Gianpietro
AU - Turazzi, Sergio
AU - Monfardini, Silvio
PY - 2000/1/1
Y1 - 2000/1/1
N2 - BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.
AB - BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.
KW - Central neurocytoma
KW - Chemotherapy
KW - Recurrent
KW - Review
UR - http://www.scopus.com/inward/record.url?scp=0033970860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033970860&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0142(20000101)88:1<169::AID-CNCR23>3.0.CO;2-7
DO - 10.1002/(SICI)1097-0142(20000101)88:1<169::AID-CNCR23>3.0.CO;2-7
M3 - Article
C2 - 10618620
AN - SCOPUS:0033970860
VL - 88
SP - 169
EP - 174
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 1
ER -